Worse, though, imagine being asked how much money you have in your bank account, perhaps after expressing interest in the cheapest bottle of wine on the menu. Worse than that, imagine that your date asks what your credit rating is, perhaps after you suggest splitting the bill with a modest tip. Even worse, perhaps as you exit the faux-fancy restaurant and head to the bus stop, imagine your date asks directly, how much credit card debt do you have?
Top 10 Small Cap Companies To Watch In Right Now: Stratasys Inc.(SSYS)
Stratasys, Inc., together with its subsidiaries, engages in the development, manufacture, marketing, and servicing of three-dimensional (3D) printers, rapid prototyping (RP) systems, and related consumable materials for office-based RP and direct digital manufacturing (DDM) markets. The company offers its products as integrated systems consisting of an RP machine and the software to convert the CAD designs into a machine compatible format, and modeling and support materials. Its products enable engineers and designers to create physical models, tooling, jigs, fixtures, prototypes, and end use parts out of production grade thermoplastic directly from a CAD workstation. The company also offers rapid prototyping and production part manufacturing services; and maintenance, leasing/renting, training, and contract engineering services for 3D production systems and 3D printers. Its products are used by design and manufacturing organizations in aerospace, architecture, automotive, business machines, consumer products, defense, direct digital manufacturing of custom parts, educational institutions, electronics, fixtures, jewelry, heavy equipment, medical systems, tooling, medical analysis, mold making, and dental markets. The company markets its products through a network of value-added resellers and distributors in the Americas, Europe, the Middle East, Korea, Taiwan, Japan, and China. Stratasys, Inc. was founded in 1989 and is headquartered in Eden Prairie, Minnesota.
Advisors' Opinion:- [By Keith Fitz-Gerald]
In the large-scale and manufacturing space, I like Stratasys Ltd. (Nasdaq: SSYS). It's already a leader in 3D printing and is investing heavily in the new materials that will make 4D possible. The company trades at $109 and has a $4.29 billion market cap. The latest data reflect earnings of -0.55 per share, but that may be misleading if the company really taps the potential I believe 4D represents.
- [By shash63]
The 3D printing industry is flying high and leading 3D printer manufacturers are reaping the benefit of this high flying market. The market for 3D printers is projected to grow by 500% in the next five years. Stratasys (SSYS) is one such company that is keeping its growth intact despite stringent competition from rivals like 3D Systems.
- [By James E. Brumley]
They say the great ones withstand the test of time. If that's true of stocks (and it is), then it's becoming increasingly safer to say Makism 3D Corp. (OTCMKTS:MDDD) is one of the great ones within the 3D printing world. No, it's neither as big nor as prolific as 3D printer names like 3D Systems Corporation (NYSE:DDD) or Stratasys, Ltd. (NASDAQ:SSYS). Then again, everything is relative; MDDD may well be packing more of a punch for its investors than SSYS or DDD have in a long time.
- [By Selena Maranjian]
The biggest new holdings are Liberty Media�and Dollar General. Other new holdings of interest include Stratasys (NASDAQ: SSYS ) . 3-D printing specialist Stratasys has been surging in recent years, posting double-digit (and accelerating) revenue growth and topping analyst estimates. Bulls like strong sales growth for the composite material used in its printers, but bears worry that the stock has gotten ahead of itself and don't like a drop in free cash flow.
Top Cheapest Stocks To Invest In 2014: SPDR DB International Government Inflation-Protected Bond ETF (WIP)
SPDR DB International Government Inflation-Protected Bond ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the DB Global Government ex-US Inflation-Linked Bond Capped Index (the Index). The Index measures the performance of the inflation-linked government bond markets of developed and emerging market countries outside of the United States. Inflation protected public obligations of the inflation-linked government bond markets of developed and emerging market countries, commonly known in the United States as treasury inflation-protected securities (TIPS), are securities issued by such governments that are designed to provide inflation protection to investors. The Fund uses a passive management strategy to track the Index. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:- [By Richard Stavros]
With respect to inflation protected bonds, though TIPS should be a part of every portfolio. However, we believe the SPDR DB International Government Inflation-Protected Bond (WIP) offers greater protection than TIPS.
Top Cheapest Stocks To Invest In 2014: Weyco Group Inc.(WEYS)
Weyco Group, Inc. engages in the distribution of men?s foot wear primarily in the United States, Canada, Europe, Australia, Asia, and South Africa. It offers casual, dress, and fashion shoes. The company offers its products under the brand names of Florsheim, Nunn Bush, Stacy Adams, Umi, Brass Boot, and Nunn Bush NXXT. Weyco Group sells its products to shoe specialty stores, department stores, and clothing retailers. As of December 31, 2010, it owned 35 retail stores in the United States and an Internet business. The company was formerly known as Weyenberg Shoe Manufacturing Company and changed its name to Weyco Group, Inc. in April 1990. Weyco Group, Inc. was founded in 1896 and is based in Milwaukee, Wisconsin.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Weyco Group (Nasdaq: WEYS ) , whose recent revenue and earnings are plotted below.
Top Cheapest Stocks To Invest In 2014: Universal Health Services Inc. (UHS)
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The company�s hospitals offer various services comprising general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2012, it owned and/or operated 25 acute care hospitals and 198 behavioral health centers located in 36 states, Puerto Rico, and the U.S. Virgin Islands, as well as Washington, D.C. The company also operates six surgical hospitals, and surgery and radiation oncology centers located in four states and Puerto Rico. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Advisors' Opinion:- [By Asit Sharma]
Universal Health Services (NYSE: UHS )
King of Prussia, Pa.-based Universal Health Services�operates acute-care hospitals and behavioral health centers in the United States and the U.S. Virgin Islands.The company books more than $7 billion in annual revenue, and has grown its quarterly earnings more than 220% over the last five years.� - [By Rich Duprey]
Hospital chain operator�Universal Health Services� (NYSE: UHS ) announced today its third-quarter dividend of $0.05 per share, the same rate it's paid since 2010.
- [By Lee Jackson]
Universal Health Services Inc. (NYSE: UHS) is well liked at J.P. Morgan, as coverage expansion under reform provides a substantial boost in 2014. The company’s focus is on behavioral health, which is in a comparatively more attractive position over acute care, the differentiating degree of diversification with behavioral health providers and its market leadership within acute care facilities in high-growth areas. The bottom line is mental health is a growing field. The J.P. Morgan target is raised from $74 to $86.
- [By John Moore]
Universal Health Services (NYSE: UHS ) has aggressively attacked a grown concern in America: diabetes. The company is currently developing specialty services to treat type 1 diabetes and mental health.�Universal Health Services provides expert home, hospice and personal assistance care. They specialize in providing nurses who are skilled in diabetes and disease management.�
Top Cheapest Stocks To Invest In 2014: PennyMac Mortgage Investment Trust(PMT)
PennyMac Mortgage Investment Trust is based in the United States.
Advisors' Opinion:- [By Jon C. Ogg]
Sterne Agee’s team said, “We continue to prefer credit risk oriented Mortgage REITs over their Agency-only focused counterparts. Among the larger cap names in our coverage, our top picks are MFA Financial, Inc. (NYSE: MFA) and PennyMac Mortgage Investment Trust (NYSE: PMT).”
- [By Sally Jones] ng>Current Shares: 3,570,000
Value: $80,968,000
Weighting: 19.8%
Down 9% over 12 months, PennyMac Mortgage Investment Trust, a residential REIT, has a market cap of $1.61 billion; its shares were traded at around $22.94 with a P/E of 7.30. The dividend yield is 10%.
PMT is not ranked for business predictability.
Track historical data:
Guru Action: As of Sept. 30, 2013, Kyle Bass made a new buy of 3,570,000 shares at an average price of $21.84 per share, for a gain of 4.3%.
The GuruFocus analysis of PMT shows five warning signs.
Vodafone Group PLC (VOD)
Current Shares: 1,349,200
Value: $47,465,000
Weighting: 11.6%
Up 55% over 12 months, Vodafone Group PLC has a market cap of $189.2 billion; its shares were traded at around $39.14 with a P/E of 273.80. The dividend yield is 4.00%.
Vodafone Group PLC is a provider of mobile communications services and products in Germany, Italy, Spain, UK, Europe, India and Africa, Middle East and Asia Pacific.
GuruFocus ranked VOD with one out of five stars for business predictability.
Track historical data:
Guru Action: As of Sept. 30, 2013, Kyle Bass made a new buy of 1,349,200 shares at an average price of $31.01 per share, for a gain of 25.9%.
The GuruFocus analysis of VOD shows nine warning signs.
Microsoft Corporation (MSFT)
Current Shares: 1,500,000
Value: $49,920,000
Weighting: 12.2%
Up 38% over 12 months, Microsoft Corporation has a market cap of $309.54 billion; its shares were traded at around $37.45 with a P/E of 13.70. The dividend yield is 2.60%.
GuruFocus ranked MSFT with three out of five stars for business predictability.
Track historical data:
Guru Action: As of Sept. 30, 2013, Kyle Bass made a new buy of 1,500,000 shares at an average price of $32.90 per share, for a gain of 12.7%.
The GuruFocus analysis of MSFT shows two go
Top Cheapest Stocks To Invest In 2014: Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.
Rigosertib
Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.
ON 013105
The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.
Recilisib
The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.
Preclinical Programs
The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.
The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 clinical-state biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Onconova Therapeutics (ONTX), which focuses on discovering and developing small molecule drug candidates to treat cancer. This stock has been destroyed by the short-sellers so far in 2014, with shares off sharply by 56%.
If you glance at the chart for Onconova Therapeutics, you'll notice that this stock has been trending sideways and consolidating right below its 50-day moving average for the last few weeks. This consolidation pattern is occurring right after shares of ONTX recently spiked sharply higher from its low of $4.10 to its high of $5.52 a share. Shares of ONTX are now trending within range of breaking out of that consolidation pattern and potentially heading higher.
Traders should now look for long-biased trades in ONTX if it manages to break out above its 50-day moving average of $5.09 a share and then once it takes out some more key overhead resistance levels at $5.24 to $5.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 203,756 shares. If that breakout triggers soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $6.27 to $7 a share.
Traders can look to buy ONTX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.75 to right around $4.50 a share. One can also buy ONTX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By gurujx]
Onconova Therapeutics Inc (ONTX) Reached the 3-year Low of $4.18
The prices of Onconova Therapeutics Inc (ONTX) shares have declined to close to the 3-year low of $4.18, which is 86.8% off the 3-year high of $31.13.
- [By Roberto Pedone]
Onconova Therapeutics (ONTX), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. This stock closed up 2.5% to $5.15 in Thursday's trading session.
Thursday's Range: $4.97-$5.19
52-Week Range: $4.10-$31.13
Thursday's Volume: 132,000
Three-Month Average Volume: 216,102From a technical perspective, ONTX trended modestly higher here with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $4.10 to its recent high of $5.52. During that uptrend, shares of ONTX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ONTX within range of triggering a near-term breakout trade. That trade will hit if ONTX manages to take out Thursday's intraday high of $5.19 to some more key overhead resistance at $5.52 with high volume.
Traders should now look for long-biased trades in ONTX as long as it's trending above some near-term support levels at $4.80 or at $4.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 216,102 shares. If that breakout gets underway soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $5.83 to $6.27. Any high-volume move above those levels will then give ONTX a chance to tag $7.
No comments:
Post a Comment